学术发表 - 合源生物科技（天津）有限公司

Research and Development 科研管线

纳基奥仑赛认证医疗机构名单创新支付研发管线学术发表

发表时间：2020/07/14 来源：British Journal of Haematology

Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy
发表时间：2019/12/12 来源：Blood - 2019 ASH Annual Meeting Abstract

Phase 1 Results of CNCT19: CD19 CAR Constructed of a New Anti-CD19 Chimeric Antigen Receptor in Relapsed or Refractory Acute Lymphoblastic Leukemia.
发表时间：2019/12/12 来源：Blood - 2019 ASH Annual Meeting Abstract

The Risk of Hepatitis B Reactivation Is Controllable in Patients with Concomitant Hepatitis B Virus Infection during Chimeric Antigen Receptor T-Cell Therapy

1 2 3 4

我们的目标专注细胞治疗领航健康未来